Seeking Alpha

Genetic Tech debuts two new cancer tests; shares ahead 15% premarket

|About: Genetic Technologies L... (GENE)|By:, SA News Editor

Thinly traded nano cap Genetic Technologies (NASDAQ:GENE) is up 15% premarket on light volume in response to its announcement of two new tests, one for assessing the risk of colorectal cancer cancer and the other for risk of breast cancer.

The company plans to launch the tests, called GeneType for Colorectal Cancer and GeneType for Breast Cancer, through a global network of distribution partners (it is working with TGen in the U.S.).

Subscribe for full text news in your inbox